2026-04-29T00:59:58Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/235832024-11-29T03:00:41Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Gutierrez, Antonio author Alonso, Aser author Garcia-Recio, Marta author Perez, Sandra author Garcia-Maño, Lucia author Martinez-Serra, Jordi author Ros, Teresa author García-Gasalla, Mercedes author Ferrer, Joana author Vögler, Oliver author Alemany, Regina author Salar, Antonio author Sampol Mayol, Antonia author Bento, Leyre 2024-10-09T06:33:32Z 2024-10-09T06:33:32Z 2023 Gutierrez A, Alonso A, Garcia-Recio M, Perez S, Garcia-Maño L, Martinez-Serra J, et al. Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience. Front Immunol. 2023 Nov 1;14. https://hdl.handle.net/20.500.13003/20022 https://hdl.handle.net/20.500.12105/23583 38022668 10.3389/fimmu.2023.1267485 1664-3224 Frontiers in immunology 2-s2.0-85176546417 1101673300001 L2026604012 Introduction: The use of maintenance approaches with anti-CD20 monoclonal antibodies has improved the outcomes of B-cell indolent lymphomas but may lead to significant peripheral B-cell depletion. This depletion can potentially hinder the serological response to neoantigens. Methods: Our objective was to analyze the effect of anti-CD20 maintenance therapy in a reliable model of response to neoantigens: SARS-CoV-2 vaccine responses and the incidence/severity ofCOVID-19 in a reference hospital. Results: In our series (n=118), the rate of vaccination failures was 31%. Through ROC curve analysis, we determined a cutoff for SARS-CoV-2 vaccine serologic response at 24 months from the last anti-CD20 dose. The risk of severe COVID-19 was notably higher within the first 24months following the last anti-CD20 dose (52%) compared to after this period (just 18%) (p=0.007). In our survival analysis, neither vaccine response nor hypogammaglobulinemia significantly affected OS. While COVID-19 led to a modest mortality rate of 2.5%, this figure was comparable to the OS reported in the general immunocompetent population. However, most patients with hypogammaglobulinemia received intravenous immunoglobulin therapy and all were vaccinated. In conclusion, anti-CD20 maintenance therapy impairs serological responses to SARS-CoV-2 vaccines. Discussion: We report for the first time that patients during maintenance therapy and up to 24 months after the last anti-CD20 dose are at a higher risk of vaccine failure and more severe cases of COVID-19. Nevertheless, with close monitoring, intravenous immunoglobulin supplementation or proper vaccination, the impact on survival due to the lack of serological response in this high-risk population can be mitigated, allowing for the benefits of anti-CD20 maintenance therapy, even in the presence of hypogammaglobulinemia. eng Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience research article